📣 VC round data is live. Check it out!

Iridex Valuation Multiples

Discover revenue and EBITDA valuation multiples for Iridex and similar public comparables like Geratherm Medical, Scandinavian Real Heart, Co-Diagnostics, Inspira Technologies and more.

Iridex Overview

About Iridex

IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.


Founded

1989

HQ

United States

Employees

93

Website

iridex.com

Financials (LTM)

Revenue: $53M
EBITDA: $2M

EV

$23M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Iridex Financials

Iridex reported last 12-month revenue of $53M and EBITDA of $2M.

In the same LTM period, Iridex generated $20M in gross profit, $2M in EBITDA, and had net loss of ($3M).

Revenue (LTM)


Iridex P&L

In the most recent fiscal year, Iridex reported revenue of $53M and EBITDA of $2M.

Iridex is unprofitable as of last fiscal year, with gross margin of 36%, EBITDA margin of 5%, and net margin of (2%).

See analyst estimates for Iridex
LTMLast FY202320242025202620272028
Revenue$53M$53M$52M$49M$53M
Gross Profit$20M$19M$22M$20M$19M
Gross Margin38%36%42%40%37%
EBITDA$2M$2M($8M)($7M)$1M
EBITDA Margin3%5%(15%)(14%)2%
EBIT Margin(3%)(1%)(19%)(17%)(5%)
Net Profit($3M)($795K)($10M)($9M)($4M)
Net Margin(6%)(2%)(18%)(18%)(8%)

Financial data powered by Morningstar, Inc.

Iridex Stock Performance

Iridex has current market cap of $18M, and enterprise value of $23M.

Market Cap Evolution


Iridex's stock price is $1.01.

Iridex share price decreased by 3.3% in the last 30 days, and increased by 1.2% in the last year.

Iridex has an EPS (earnings per share) of $-0.05.

See more trading valuation data for Iridex
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$23M$18M0.0%-3.3%-27.4%1.2%$-0.05

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Iridex Valuation Multiples

Iridex trades at 0.4x EV/Revenue multiple, and 14.0x EV/EBITDA.

See NTM and 2027E valuation multiples for Iridex

EV / Revenue (LTM)


Iridex Financial Valuation Multiples

As of May 26, 2026, Iridex has market cap of $18M and EV of $23M.

Iridex has a P/E ratio of (5.9x).

LTMLast FY202320242025202620272028
EV/Revenue0.4x0.4x0.4x0.5x0.4x
EV/EBITDA14.0x9.5x(2.9x)(3.4x)20.7x
EV/EBIT(14.1x)(87.8x)(2.3x)(2.8x)(9.0x)
EV/Gross Profit1.2x1.2x1.1x1.2x1.2x
P/E(5.9x)(22.1x)(1.8x)(2.0x)(4.0x)
EV/FCF(10.3x)(3.4x)(3.2x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Iridex Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Iridex Margins & Growth Rates

Iridex grew revenue by 7% and EBITDA by 48% in the last fiscal year.

In the most recent fiscal year, Iridex reported gross margin of 36%, EBITDA margin of 5%, and net margin of (2%).

See estimated margins and future growth rates for Iridex

Iridex Margins

Last FY202420252026202720282029
Gross Margin36%40%37%37%
EBITDA Margin5%(14%)2%(2%)
EBIT Margin(1%)(17%)(5%)(5%)
Net Margin(2%)(18%)(8%)(8%)
FCF Margin(4%)(15%)(4%)

Iridex Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth7%(6%)8%0%
Gross Profit Growth20%(11%)(1%)0%
EBITDA Growth48%(14%)(116%)(191%)
EBIT Growth(402%)(17%)(69%)0%
Net Profit Growth(145%)(7%)(50%)0%
FCF Growth6%

Data powered by FactSet, Inc. and Morningstar, Inc.

Iridex Operational KPIs

Iridex's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.2M for the same period.

Iridex's Rule of 40 is (2%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Iridex's Rule of X is (2%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Iridex
LTMLast FY202320242025202620272028
Rule of 406%(2%)
Bessemer Rule of X11%(2%)
Revenue per Employee$0.6M
Opex per Employee$0.2M
S&M Expenses to Revenue20%20%31%26%20%
G&A Expenses to Revenue14%15%17%20%15%
R&D Expenses to Revenue7%7%13%11%7%
Opex to Revenue41%61%57%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Geratherm Medical0.4x2.7x
Scandinavian Real Heart(4.1x)
Co-Diagnostics19.9x19.9x(0.4x)
Inspira Technologies0.7x(3.8x)
Labo Euromedis0.2x7.7x
Icecure Medical3.3x2.4x(0.8x)
Lifeward0.8x0.7x(1.0x)
ViroGates9.3x(8.0x)

This data is available for Pro users. Sign up to see all Iridex competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Iridex

When was Iridex founded?Iridex was founded in 1989.
Where is Iridex headquartered?Iridex is headquartered in United States.
How many employees does Iridex have?As of today, Iridex has over 93 employees.
Who is the CEO of Iridex?Iridex's CEO is Patrick Mercer.
Is Iridex publicly listed?Yes, Iridex is a public company listed on Nasdaq.
What is the stock symbol of Iridex?Iridex trades under IRIX ticker.
When did Iridex go public?Iridex went public in 1996.
Who are competitors of Iridex?Iridex main competitors include Geratherm Medical, Scandinavian Real Heart, Co-Diagnostics, Inspira Technologies, Labo Euromedis, Icecure Medical, Lifeward, ViroGates, Conneqt Health, Advanced Medical.
What is the current market cap of Iridex?Iridex's current market cap is $18M.
What is the current revenue of Iridex?Iridex's last 12 months revenue is $53M.
What is the current revenue growth of Iridex?Iridex revenue growth (NTM/LTM) is 3%.
What is the current EV/Revenue multiple of Iridex?Current revenue multiple of Iridex is 0.4x.
Is Iridex profitable?Yes, Iridex is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of Iridex?Iridex's last 12 months EBITDA is $2M.
What is Iridex's EBITDA margin?Iridex's last 12 months EBITDA margin is 3%.
What is the current EV/EBITDA multiple of Iridex?Current EBITDA multiple of Iridex is 14.0x.
How many companies Iridex has acquired to date?Iridex hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Iridex has invested to date?Iridex hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Iridex

Lists including Iridex

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial